Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:8/27/2008

PALO ALTO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 34 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 73,700 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it ... fiscal year 2010 on December 10, 2009 at 7:00 a.m. ... discuss the results at 11:30 a.m. EST on the same ... the second quarter ended October 31, 2009 and will review ...
(Date:12/3/2009)... Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: ... services for drug discovery and life sciences research, today ... imaging systems. Living Image software drives the more than ... Living Image 4.0 features advanced spectral unmixing tools to ...
(Date:12/2/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) announced today that ... and fiscal year 2009 on December 16, 2009, at approximately ... 4:45 p.m. ET Martek will conduct a conference call to ... listen to the call live via webcast by visiting Martek,s ...
(Date:12/2/2009)... Dec. 2 Reportlinker.com announces that a ... its catalogue: ,, Neurostimulation - A ... ,, The world neurostimulation market ... aging population, and the resultant rise in ...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
... Before R&D up 19% - Net Profit (Group Share) up 12% - Acceleration of R&D Expenditure ... (EUR millions) 2007 As a % ... ... 147.1 ...
... and Portfolio in Pain ... ... Inc. (OTC Bulletin Board: CAXG), which has the,largest manufacturing facility and ... today announced that Hebei,Aoxing Pharmaceutical Group Company, the subsidiary of China ...
... General Research Laboratory,Inc. (GRL) and Sirnaomics, Inc. ... partnership initiated in July 2007 for development ... the successful,identification of siRNA inhibitors for multi-targeted ... silico and in vitro studies, using,Sirnaomics, Tri-Blocker(TM) ...
Other Biology Technology:STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 2STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 3China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. 2China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. 3Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 3
(Date:12/3/2009)... by a social snubbing? Your genetics, not your friends, may ... painkillers, called opioids, relieve not only physical pain, but also ... by Faculty of 1000 Biology member Markus Heilig shows that ... can determine the intensity of people,s responses to social rejection. ...
(Date:12/3/2009)... from the U.S. Department of Energy,s (DOE) Brookhaven National ... has made a major step in understanding how molecules ... to carry out important biological processes. The research, published ... Structural & Molecular Biology , confirms that many proteins ...
(Date:12/2/2009)... that people who smoke cigarettes over a long period ... cancer, even after adjusting for other risk factors. ... or to quit as soon as possible," said senior ... epidemiology and surveillance research at the American Cancer Society. ...
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Cigarette smoking increases colorectal cancer risk 2San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 1San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 2San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 3Michael J Fox Foundation Commits Up to 2412 Million for Targeted Parkinsons Therapeutic Development in 2010 5007 1Michael J Fox Foundation Commits Up to 2412 Million for Targeted Parkinsons Therapeutic Development in 2010 5007 2Michael J Fox Foundation Commits Up to 2412 Million for Targeted Parkinsons Therapeutic Development in 2010 5007 3Michael J Fox Foundation Commits Up to 2412 Million for Targeted Parkinsons Therapeutic Development in 2010 5007 4Weighing costs benefits of HIV treatments 57258 1Weighing costs benefits of HIV treatments 57258 2Weighing costs benefits of HIV treatments 57258 3
... because undifferentiated cells with features typical of stem cells ... brain, and muscles, scientists are beginning to assume that ... from the Max Planck Institute for Heart and Lung ... a study published in the journal Molecular and Cellular ...
... a plethora of dog genome-related materials are published, including a ... and a series of primary research articles in the journal ... publication by Nature of a high-quality draft sequence ... and the public with informative resources about canine genomics and ...
... and over during the bowl and NFL playoff seasons: a ... hitting the back of his head on the landing. , ... the skull? Researchers and doctors long have relied upon ... that infer ?rather loosely ?what happens to the brain during ...
Other Biology News:Forgotten by evolution? 2Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4New technique puts brain-imaging research on its head 2New technique puts brain-imaging research on its head 3
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... 2b GenBank Accession Number ... peptide (C-QSQENQDTRPKVKAKK), corresponding to amino ... 2b Formulation: antiserum in 0.05% ... Quality Assurance: routinely evaluated by ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: